Acute myeloid leukemia, Myelodysplastic syndrome
VORVor BiopharmaCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Trem-cel (VOR33) + Mylotarg (VBP101) in Acute myeloid leukemia, Myelodysplastic syndrome. The expected timing is based on the latest available company guidance and may change.
VBP101 trial. 12/9/24- Clinical data reported. Received supportive feedback from FDA for a registrational trial design. 3/20/25- Report follow up data in H2 2025. 5/8/25- Discontinued all clinical and manufacturing operations, including ongoing clinical trials. 08/11/26:- UPSTREAM MG enrollment ongoing; topline data still anticipated in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.